CDK10

Cyclin-dependent kinase 10

229 patent compounds predicted against CDK10, 188 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29421607	1.00	1/20
SCHEMBL30405852	1.00	1/20
SCHEMBL29648491	0.73	1/20
SCHEMBL29975793	0.73	1/20
SCHEMBL30094663	0.73	1/20
SCHEMBL30273058	0.73	1/20
SCHEMBL30319807	0.73	1/20
SCHEMBL30597674	0.73	1/20
SCHEMBL30597679	0.73	1/20
SCHEMBL9963854	0.72	1/20
SCHEMBL30380971	0.70	1/20
SCHEMBL23064865	0.70	1/20
SCHEMBL29353719	0.70	1/20
SCHEMBL30319805	0.68	1/20
SCHEMBL29961097	0.68	1/20
SCHEMBL30597663	0.68	1/20
SCHEMBL30319763	0.67	1/20
SCHEMBL30319777	0.67	1/20
SCHEMBL30319862	0.67	1/20
SCHEMBL15113154	0.65	1/20

Germline variants in CDK10 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK10 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
RP-6306 in Patients With Advanced Cancer	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma	PHASE1	WITHDRAWN
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics	PHASE1	RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK10 binder may also engage these)

Protein	Name	Similarity
Q3UMM4	—	1.000	Q3UMM4 →
Q2TBL8	—	1.000	Q2TBL8 →
Q4KM47	—	0.998	Q4KM47 →
Q80YP0	—	0.984	Q80YP0 →
CDK2	Cyclin-dependent kinase 2	0.981	landscape →
P43450	—	0.980	P43450 →
P21708	—	0.979	P21708 →
P48963	—	0.979	P48963 →
CDK3	Cyclin-dependent kinase 3	0.978	landscape →
Q63699	—	0.978	Q63699 →
Q63844	—	0.977	Q63844 →
Q40884	—	0.977	Q40884 →
P97377	—	0.976	P97377 →
O55076	—	0.976	O55076 →
P34112	—	0.976	P34112 →
Q5E9Y0	—	0.976	Q5E9Y0 →
Q6Z437	—	0.976	Q6Z437 →
P51958	—	0.976	P51958 →
MAPK3	Mitogen-activated protein kinase 3	0.976	landscape →
Q2PQN9	—	0.975	Q2PQN9 →
Q26671	—	0.975	Q26671 →
P29619	—	0.974	P29619 →
Q39022	—	0.974	Q39022 →
P29618	—	0.974	P29618 →
P93101	—	0.974	P93101 →
MAPK14	Mitogen-activated protein kinase 14	0.973	landscape →
Q9DG98	—	0.973	Q9DG98 →
P27638	—	0.973	P27638 →
Q41639	—	0.973	Q41639 →
Q38773	—	0.973	Q38773 →